Full Breakdown
India Advances Towards a Single-Dose Dengue Vaccine
2/27/2026, 10:12:48 PM
DengiAll Enters Final Testing Phase
Indian pharmaceutical company Panacea Biotec has initiated Phase III clinical trials for its dengue vaccine candidate, DengiAll, after nearly 15 years of research and development. The trials, which began in 2024, involve over 10,000 volunteers across India and are overseen by the Indian Council of Medical Research (ICMR). If the results are favorable, DengiAll could be rolled out as early as 2027, marking a significant milestone as one of the world’s first single-dose dengue vaccines.
Dengue fever, a mosquito-borne disease, has surged globally, with the World Health Organization (WHO) estimating that nearly half of the world’s population is at risk, leading to 100-400 million infections annually. In India, over one million cases and at least 1,500 deaths have been reported since 2021. The urgency for a vaccine is underscored by the hyperendemic nature of dengue in India, where all four virus serotypes circulate simultaneously.
Scientific Challenges and Vaccine Development
Developing a dengue vaccine has historically posed significant challenges due to the existence of four distinct serotypes. Immunity to one serotype does not guarantee protection against others, and secondary infections can be more severe. Most existing candidates require multiple doses, complicating mass vaccination efforts. DengiAll is based on a tetravalent strain originally developed by the US National Institutes of Health and aims to provide protection against all four serotypes with a single dose.
Dr. Ekta Gupta, a professor of clinical virology at the Institute of Liver and Biliary Sciences in New Delhi, emphasized the critical need for this vaccine to control dengue cases and mitigate severity, particularly among children who are more vulnerable to severe complications.
Climate Change and Dengue Incidence
Rising temperatures and changing rainfall patterns have created ideal conditions for Aedes mosquitoes, the primary vectors of dengue. Public health experts warn that if current climate trends continue, dengue incidence could increase by 50-75% by 2050, expanding the geographic range of outbreaks and exposing new populations to the virus.
Regulatory Oversight and Future Prospects
Panacea Biotec is committed to ensuring the safety and efficacy of DengiAll. Dr. Priyanka Priyadarsiny, head of biological research and development at Panacea, stated that the company is "extremely cautious about purity, safety, and adverse effects." Approval in India would come from the Drug Controller General of India, while WHO prequalification would be necessary for international distribution.
Currently, the WHO recommends only one dengue vaccine, Qdenga, produced by Takeda Pharmaceutical Company, which requires two doses and is not available in India. A successful Indian-made vaccine could enhance affordability and access, particularly in lower- and middle-income countries.
Expert Opinions and Optimism
Experts remain cautiously optimistic about the potential of DengiAll. Virologist Shahid Jameel from Oxford University noted that while Phase III results are crucial for determining the vaccine's safety and efficacy, there is hope for the future. If approved, DengiAll could represent a significant advancement in global dengue prevention, offering a scalable, single-dose solution at a critical time.
Verbatim Quotes
- “We will try to get this vaccine out there as soon as possible,” — Syed Khalid Ali, Chief Scientific Officer, Panacea Biotec
- “This vaccine is very much needed right now to control the occurrence of these cases, or at least prevent the severity.” — Dr. Ekta Gupta, Professor of Clinical Virology, Institute of Liver and Biliary Sciences
- “Only after meeting regulatory specifications can a product be considered safe for public use.” — Dr. Priyanka Priyadarsiny, Head of Biological R&D, Panacea Biotec
- “Phase III testing and follow-up are needed to show if the above conditions are met,” — Shahid Jameel, Virologist, Oxford University
